# A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

> **NCT00095225** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma
- Neoplasm Recurrence, Local

## Interventions

- **DRUG:** Avastin (bevacizumab)
- **DRUG:** Tarceva (erlotinib HCl)

## Key facts

- **NCT ID:** NCT00095225
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2008-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095225, "A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00095225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*